CD34 and acute myeloid leukemia: We further demonstrated that VISTA antibody on IgG4-Pro backbone increased the interaction of effector immune cells with CD34+ AML cancer cells in ex vivo patient samples; that effect was similarly reduced by an IgG1-KO backbone.